BACKGROUND: Patient-derived xenograft (PDX) models increasingly are used in translational research. However, the engraftment rates of patient tumor samples in immunodeficient mice to PDX models vary greatly. METHODS: Tumor tissue samples from 308 patients with non-small cell lung cancer were implanted in immunodeficient mice. The patients were followed for 1.5 to approximately 6 years. The authors performed histological analysis of PDXs and some residual tumor tissues in mice with failed PDX growth at 1 year after implantation. Quantitative polymerase chain reaction and enzyme-linked immunoadsorbent assay were performed to measure the levels of Epstein-Barr virus genes and human immunoglobulin G in PDX samples. Patient characteristics were compared for PDX growth and overall survival as outcomes using Cox regression analyses. Disease staging was based on the 7th TNM staging system. RESULTS: The overall engraftment rate for PDXs from patients with non-small cell lung cancer was 34%. Squamous cell carcinomas had a higher engraftment rate (53%) compared with adenocarcinomas. Tumor samples from patients with stage II and stage III disease and from larger tumors were found to have relatively high engraftment rates. Patients whose tumors successfully engrafted had worse overall survival, particularly those individuals with adenocarcinoma, stage III or stage IV disease, and moderately differentiated tumors. Lymphoma formation was one of the factors associated with engraftment failure. Human CD8-positive and CD20-positive cells were detected in residual samples of tumor tissue that failed to generate a PDX at 1 year after implantation. Human immunoglobulin G was detected in the plasma of mice that did not have PDX growth at 14 months after implantation. CONCLUSIONS: The results of the current study indicate that the characteristics of cancer cells and the tumor immune microenvironment in primary tumors both can affect engraftment of a primary tumor sample.
BACKGROUND:Patient-derived xenograft (PDX) models increasingly are used in translational research. However, the engraftment rates of patienttumor samples in immunodeficientmice to PDX models vary greatly. METHODS:Tumor tissue samples from 308 patients with non-small cell lung cancer were implanted in immunodeficientmice. The patients were followed for 1.5 to approximately 6 years. The authors performed histological analysis of PDXs and some residual tumor tissues in mice with failed PDX growth at 1 year after implantation. Quantitative polymerase chain reaction and enzyme-linked immunoadsorbent assay were performed to measure the levels of Epstein-Barr virus genes and humanimmunoglobulin G in PDX samples. Patient characteristics were compared for PDX growth and overall survival as outcomes using Cox regression analyses. Disease staging was based on the 7th TNM staging system. RESULTS: The overall engraftment rate for PDXs from patients with non-small cell lung cancer was 34%. Squamous cell carcinomas had a higher engraftment rate (53%) compared with adenocarcinomas. Tumor samples from patients with stage II and stage III disease and from larger tumors were found to have relatively high engraftment rates. Patients whose tumors successfully engrafted had worse overall survival, particularly those individuals with adenocarcinoma, stage III or stage IV disease, and moderately differentiated tumors. Lymphoma formation was one of the factors associated with engraftment failure. HumanCD8-positive and CD20-positive cells were detected in residual samples of tumor tissue that failed to generate a PDX at 1 year after implantation. Humanimmunoglobulin G was detected in the plasma of mice that did not have PDX growth at 14 months after implantation. CONCLUSIONS: The results of the current study indicate that the characteristics of cancer cells and the tumor immune microenvironment in primary tumors both can affect engraftment of a primary tumor sample.
Authors: Xiang Yan; Xiaoshan Zhang; Li Wang; Ran Zhang; Xingxiang Pu; Shuhong Wu; Lei Li; Pan Tong; Jing Wang; Qing H Meng; Vanessa B Jensen; Luc Girard; John D Minna; Jack A Roth; Stephen G Swisher; John V Heymach; Bingliang Fang Journal: Cancer Res Date: 2018-11-06 Impact factor: 12.701
Authors: R Perez-Soler; B Kemp; Q P Wu; L Mao; J Gomez; A Zeleniuch-Jacquotte; H Yee; J S Lee; J Jagirdar; Y H Ling Journal: Clin Cancer Res Date: 2000-12 Impact factor: 12.531
Authors: Hui Gao; Joshua M Korn; Stéphane Ferretti; John E Monahan; Youzhen Wang; Mallika Singh; Chao Zhang; Christian Schnell; Guizhi Yang; Yun Zhang; O Alejandro Balbin; Stéphanie Barbe; Hongbo Cai; Fergal Casey; Susmita Chatterjee; Derek Y Chiang; Shannon Chuai; Shawn M Cogan; Scott D Collins; Ernesta Dammassa; Nicolas Ebel; Millicent Embry; John Green; Audrey Kauffmann; Colleen Kowal; Rebecca J Leary; Joseph Lehar; Ying Liang; Alice Loo; Edward Lorenzana; E Robert McDonald; Margaret E McLaughlin; Jason Merkin; Ronald Meyer; Tara L Naylor; Montesa Patawaran; Anupama Reddy; Claudia Röelli; David A Ruddy; Fernando Salangsang; Francesca Santacroce; Angad P Singh; Yan Tang; Walter Tinetto; Sonja Tobler; Roberto Velazquez; Kavitha Venkatesan; Fabian Von Arx; Hui Qin Wang; Zongyao Wang; Marion Wiesmann; Daniel Wyss; Fiona Xu; Hans Bitter; Peter Atadja; Emma Lees; Francesco Hofmann; En Li; Nicholas Keen; Robert Cozens; Michael Rugaard Jensen; Nancy K Pryer; Juliet A Williams; William R Sellers Journal: Nat Med Date: 2015-10-19 Impact factor: 53.440
Authors: Clemens Krepler; Katrin Sproesser; Patricia Brafford; Marilda Beqiri; Bradley Garman; Min Xiao; Batool Shannan; Andrea Watters; Michela Perego; Gao Zhang; Adina Vultur; Xiangfan Yin; Qin Liu; Ioannis N Anastopoulos; Bradley Wubbenhorst; Melissa A Wilson; Wei Xu; Giorgos Karakousis; Michael Feldman; Xiaowei Xu; Ravi Amaravadi; Tara C Gangadhar; David E Elder; Lauren E Haydu; Jennifer A Wargo; Michael A Davies; Yiling Lu; Gordon B Mills; Dennie T Frederick; Michal Barzily-Rokni; Keith T Flaherty; Dave S Hoon; Michael Guarino; Joseph J Bennett; Randall W Ryan; Nicholas J Petrelli; Carol L Shields; Mizue Terai; Takami Sato; Andrew E Aplin; Alexander Roesch; David Darr; Steve Angus; Rakesh Kumar; Ensar Halilovic; Giordano Caponigro; Sebastien Jeay; Jens Wuerthner; Annette Walter; Matthias Ocker; Matthew B Boxer; Lynn Schuchter; Katherine L Nathanson; Meenhard Herlyn Journal: Cell Rep Date: 2017-11-14 Impact factor: 9.423
Authors: Yonathan Lissanu Deribe; Yuting Sun; Christopher Terranova; Fatima Khan; Juan Martinez-Ledesma; Jason Gay; Guang Gao; Robert A Mullinax; Tin Khor; Ningping Feng; Yu-Hsi Lin; Chia-Chin Wu; Claudia Reyes; Qian Peng; Frederick Robinson; Akira Inoue; Veena Kochat; Chang-Gong Liu; John M Asara; Cesar Moran; Florian Muller; Jing Wang; Bingliang Fang; Vali Papadimitrakopoulou; Ignacio I Wistuba; Kunal Rai; Joseph Marszalek; P Andrew Futreal Journal: Nat Med Date: 2018-06-11 Impact factor: 53.440
Authors: S Hernández-Prieto; A Romera; M Ferrer; J L Subiza; J A López-Asenjo; J R Jarabo; A M Gómez; Elena M Molina; J Puente; J L González-Larriba; F Hernando; B Pérez-Villamil; E Díaz-Rubio; J Sanz-Ortega Journal: Clin Transl Oncol Date: 2014-10-10 Impact factor: 3.405
Authors: Kristel Kemper; Oscar Krijgsman; Xiangjun Kong; Paulien Cornelissen-Steijger; Aida Shahrabi; Fleur Weeber; Daphne L van der Velden; Onno B Bleijerveld; Thomas Kuilman; Roel J C Kluin; Chong Sun; Emile E Voest; Young Seok Ju; Ton N M Schumacher; A F Maarten Altelaar; Ultan McDermott; David J Adams; Christian U Blank; John B Haanen; Daniel S Peeper Journal: Cell Rep Date: 2016-06-16 Impact factor: 9.423
Authors: Francesco Guerrera; Fabrizio Tabbò; Luca Bessone; Francesca Maletta; Marcello Gaudiano; Elisabetta Ercole; Laura Annaratone; Maria Todaro; Monica Boita; Pier Luigi Filosso; Paolo Solidoro; Luisa Delsedime; Alberto Oliaro; Anna Sapino; Enrico Ruffini; Giorgio Inghirami Journal: PLoS One Date: 2016-01-05 Impact factor: 3.240
Authors: Xiaoshan Zhang; Ran Zhang; Huiqin Chen; Li Wang; Chenghui Ren; Apar Pataer; Shuhong Wu; Qing H Meng; Min Jin Ha; Jeffrey Morris; Yuanxin Xi; Jing Wang; Jianhua Zhang; Don L Gibbons; John V Heymach; Funda Meric-Bernstam; John Minna; Stephen G Swisher; Jack A Roth; Bingliang Fang Journal: Am J Cancer Res Date: 2020-12-01 Impact factor: 6.166
Authors: Jacqulyne P Robichaux; Xiuning Le; R S K Vijayan; J Kevin Hicks; Simon Heeke; Yasir Y Elamin; Heather Y Lin; Hibiki Udagawa; Ferdinandos Skoulidis; Hai Tran; Susan Varghese; Junqin He; Fahao Zhang; Monique B Nilsson; Lemei Hu; Alissa Poteete; Waree Rinsurongkawong; Xiaoshan Zhang; Chenghui Ren; Xiaoke Liu; Lingzhi Hong; Jianjun Zhang; Lixia Diao; Russell Madison; Alexa B Schrock; Jennifer Saam; Victoria Raymond; Bingliang Fang; Jing Wang; Min Jin Ha; Jason B Cross; Jhanelle E Gray; John V Heymach Journal: Nature Date: 2021-09-15 Impact factor: 69.504
Authors: Xiaoshan Zhang; Ran Zhang; Chenghui Ren; Yi Xu; Shuhong Wu; Carrie Meng; Apar Pataer; Xingzhi Song; Jianhua Zhang; Yixin Yao; Hua He; Huiqin Chen; Wencai Ma; Jing Wang; Funda Meric-Bernstam; Richard E Champlin; John V Heymach; Cliona M Rooney; Stephen G Swisher; Ara A Vaporciyan; Jack A Roth; M James You; Michael Wang; Bingliang Fang Journal: Blood Adv Date: 2022-02-08